

## Gambia

### Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Gambia						
<b>2. Vaccine grant number:</b>	08-GMB-08b-Y, 0915-GMB-04C-X, 16-GMB-04c-X, 17-GMB-04c-X, 1821-GMB-04c-X, GMB-Lumpsum-1						
<b>3. Date of Decision Letter:</b>	9/30/2019						
<b>4. Date of the Partnership Framework Agreement:</b>	Sunday, February 3, 2013						
<b>5. Programme title:</b>	New Vaccine Support (NVS), DTP-HepB-Hib, Routine						
<b>6. Vaccine type:</b>	DTP-HepB-Hib						
<b>7. Requested product presentation and formulation of vaccine:</b>	Penta, 10 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2002-2021						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2002-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	9,214,045	38,500	132,500	-	-	-	9,385,045
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2002	GMB-Lumpsum-1					100,000
	2008	08-GMB-08b-Y					100,000
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	08 February, 2002						100,000
	29 September, 2008						100,000
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2002-2019	2020	2021
Number of vaccine doses		53,300	-
Annual Amounts (US\$)	9,214,045	38,500	-

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** [Enter relevant text]

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	20,500	70,500	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	14,297	49,170	-	-	-
Total co-financing payments (US\$) (including freight)	15,000	51,000	-	-	-

**16. Operational support for campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
<p><b>18. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>	
<p><b>19. Other conditions:</b></p> <p>Not applicable</p>	

Signed by,  
On behalf of Gavi



Thabani Maphosa,  
Managing Director, Country Programmes  
30/09/2019